α-Amylase/α-Glucosidase-IN-25
α-Amylase/α-Glucosidase-IN-25 is a α-Amylase inhibitor and a competitive α-Glucosidase inhibitor, with an IC50 of 10.89 μM against α-glucosidase and an IC50 of 20.62 μM against α-amylase. α-Amylase/α-Glucosidase-IN-25 limits carbohydrate digestion. α-Amylase/α-Glucosidase-IN-25 can be used in the research of type 2 diabetes.
For research use only. We do not sell to patients.
- Formula: C28H22N2O4S
- Molecular Weight:482.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
α‑glucosidase 10.89 μM (IC50) |
α-amylase 20.62 μM (IC50) |
In Vitro
α-Amylase/α-Glucosidase-IN-25 (Compound 5IT (e)) potently inhibits purified α-amylase with an IC50 of 20.62 μM[1].
As a competitive inhibitor, α-Amylase/α-Glucosidase-IN-25 potently inhibits purified α-glucosidase, with an IC50 of 10.89 μM and a Ki of 18.8 μM, exhibiting better efficacy than the reference agent Acarbose (HY-B0089)[1].
α-Amylase/α-Glucosidase-IN-25 (0-25 μM; 24 h) shows no significant cytotoxicity against HEK-293 cells, with a cell viability rate of 90% at the concentration of 25 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK-293 human embryonic kidney cells
-
Concentration:0-25 μM
-
Incubation Time:24 h
-
Result:Showed no significant cytotoxicity up to 25 μM.
Maintained 90% cell viability at 25 μM, indicating safety and biocompatibility within this dose range.
Chemical Information
-
Molecular Weight 482.55
-
Formula C28H22N2O4S
-
SMILES
O=C(N(CC(C1=CC=C(OC)C=C1)=O)C/2=O)SC2=C/C3=CN(CC4=CC=CC=C4)C5=C3C=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)